Company Description
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
It’s lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors.
The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors.
It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer.
The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.
The company was incorporated in 2019 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Tammy Furlong |
Contact Details
Address: 101 Federal Street, Suite 1900 Boston, Massachusetts 02110 United States | |
| Phone | 716 371 1125 |
| Website | elevationoncology.com |
Stock Details
| Ticker Symbol | ELEV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001783032 |
| CUSIP Number | 28623U101 |
| ISIN Number | US28623U1016 |
| Employer ID | 84-1771427 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joseph J. Ferra Jr. | Chief Executive Officer, President and Director |
| Tammy Furlong CPA, P.M.P. | Chief Financial Officer, Principal Financial and Accounting Officer and Secretary |
| Robert C. Yang | Senior Vice President and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 23, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 23, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 23, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 23, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 23, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 23, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jul 23, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jul 23, 2025 | 25-NSE | Filing |
| Jul 23, 2025 | 8-K | Current Report |
| Jul 23, 2025 | SC TO-T/A | Filing |